Gene Sciences Inc. develops DNA-targeted therapeutics that directly address human genetic diseases by utilizing precision gene editing techniques. Their approach aims to correct genetic mutations at the source, potentially improving patient outcomes and reducing the burden of hereditary conditions.
Funding
Funding not disclosed
Founders
Product
Problem
Many genetic diseases lack effective treatments because they originate from errors in the DNA sequence itself. Traditional pharmaceuticals often manage symptoms but do not address the underlying genetic cause of the disease. This leaves a significant unmet need for therapies that can directly correct or compensate for genetic mutations.
Solution
Gene Sciences Inc. is developing DNA-targeted therapeutics designed to directly address the root cause of human genetic diseases. Their approach leverages precision gene editing technologies to correct disease-causing genetic mutations at their source. By targeting the DNA sequence, the company aims to provide potentially curative treatments that can improve patient outcomes and reduce the burden of hereditary conditions. The therapeutic strategy focuses on delivering corrective genetic information to affected cells, enabling them to function normally. This approach has the potential to transform the treatment landscape for a wide range of genetic disorders.
Target Audience
The primary target audience includes patients suffering from genetic diseases, their families, and healthcare providers specializing in genetic medicine.
Features
- Utilizes CRISPR-based gene editing technology for precise DNA targeting.
- Develops customized therapeutic molecules tailored to specific genetic mutations.
- Employs proprietary delivery systems to ensure efficient and safe delivery of gene editing components to target cells.
- Focuses on in vivo gene editing, directly correcting mutations within the patient's body.